Advanced Biomed Inc. 10-Q Summary: Net income $5.98M, EPS $5.21— 10-Q Summary

Advanced Biomed Inc. reported results for the nine months ended Mar 31, 2026, recording net income of $5.98M and diluted earnings per share of $5.21, versus a net loss of $(2.56) M and diluted EPS of $(2.54) for the nine months ended Mar 31, 2025.Financial HighlightsNet income: $5.98M for the nine months ended Mar 31, 2026, versus a net loss of $(2.56) M for the nine months ended Mar 31, 2025 (YoY improvement).Diluted earnings per share: $5.21 for the nine months ended Mar 31, 2026, versus $(2.54) for the nine months ended Mar 31, 2025 (YoY improvement).Business HighlightsProduct development: Completed R&D for multiple microfluidic devices, including A+Pre, AC-1000, A+CellScan and A+SCDrop, and developed the A+PerfusC™ 3D culture system.Regulatory progress: A+Pre and AC-1000 cleared by China's NMPA; several kits and the A+LCGuard product are in registration, review or application stages in China.Commercialization: No product sales yet; commercialization is contingent on clinical trials and regulatory approvals, with sales not expected in the near term.Clinical validation: Completed a 123-case study at Shanghai Pulmonary Hospital reporting 96% sensitivity and 99.9% specificity, supporting product feasibility.Strategic moves: Sold a Hong Kong subsidiary's IP in December 2025 and acquired Acellent HK in April 2026, signaling a pivot toward AI-powered financial audit solutions.Original SEC Filing: Advanced Biomed Inc. [ ADVB ] - 10-Q - May. 15, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.